Clinical trials: H1N1/Influenza Infection
Influenza
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in non-elderly and elderly adults.
- Trial name
- NCT00973349
- Testing
- MF59-eH1N1_f
- Where
- 21 sites in United States, Mexico
- Volunteers
- 2,719 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants
A single center, observer-masked, randomized clinical trial is to be conducted in 6-35 months infants to evaluate the safety and immunogenicity of Sinovac's influenza A/H1N1 Vaccine (PANFLU.1).
- Trial name
- NCT01047202
- Testing
- Pandemic influenza A/H1N1 vaccine, Seasonal trivalent vaccine
- Where
- China
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Novel 2009 Influenza H1N1
Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 S-OIV (swine flu) vaccine in healthy young children, adolescents, and adults.
- Trial name
- NCT00973700
- Testing
- MF59-eH1N1_f, eH1N1_f
- Where
- Costa Rica
- Volunteers
- 784 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
The purpose of this study is to test the safety and efficacy of zanamivir given intravenously and how well it works at two different doses in hospitalized adolescents and adults with flu.
- Trial name
- ZORO (NCT01231620)
- Testing
- Zanamivir, Oseltamivir
- Where
- 170 sites in United States, Australia and 26 more
- Volunteers
- 626 people
- Sponsor
- GlaxoSmithKline
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00956046
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated), Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
- Where
- 15 sites in Finland
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00953524
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA), Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)
- Where
- 15 sites in United States
- Volunteers
- 849 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults
The purpose of this phase I/II trial is to evaluate safety and tolerability of a single dose of GHB16L2 administered by liquid nasal spray for vaccination against seasonal influenza virus infection.
- Trial name
- NCT01369862
- Testing
- GHB16L2
- Where
- Austria
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza A H1N1
Study of SAB-176 in Healthy Adult Participants
Healthy adult participants will be challenged with the H1N1 Influenza virus and then treated with either SAB-176 or placebo.
- Trial name
- NCT04850898
- Testing
- SAB-176
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- SAb Biotherapeutics, Inc.
Influenza
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968539
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- Belgium
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Swine-origin A/H1N1 Influenza
A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the Elderly
The purpose of this study is to generate data on immunogenicity and safety of the monovalent H1N1 vaccine in support of the development and registration.
- Trial name
- NCT00954798
- Testing
- Swine A/H1N1 influenza vaccine (split virion, inactivated)
- Where
- 6 sites in France
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Pandemic Influenza
A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents
The purpose of this study is to determine the preferred dose of H1N1 pandemic influenza vaccine in a pediatric population, aged 6 months to 17 years, based upon assessments of immunogenicity and safety.
- Trial name
- NCT00976469
- Testing
- H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated), Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011
- Where
- 6 sites in Austria, Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
H1N1 Influenza Virus, Invasive Solid Tumors
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01031719
- Testing
- adjuvanted A(H1N1) influenza vaccine, non-adjuvanted A(H1N1) influenza vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Prophylaxis of A/H3N2v Influenza
Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.
Evaluate the safety and immunogenicity of three dosage levels of swine influenza vaccine in children ages 3 to <9 years, adolescents 9 to <18 years, adults 18 to <65 years and elderly 65 years and older.
- Trial name
- NCT01855945
- Testing
- Swine Influenza
- Where
- 11 sites in United States
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in toddlers and children. Primary Objectives: To describe the immunogenicity of the candidate vaccines after each injection.
- Trial name
- NCT00952419
- Testing
- Monovalent Subvirion A/H1N1 Influenza vaccine
- Where
- 20 sites in United States
- Volunteers
- 474 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Seasonal Human Influenza
Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers
The purpose of this phase I trial is to evaluate safety and tolerability of GHB01L1 administered as single dose intranasal aerosol for vaccination against influenza A (H1N1) virus.
- Trial name
- GHBCS-01 (NCT00724997)
- Testing
- GHB01L1
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AVIR Green Hills Biotechnology AG
Influenza
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USA
The purpose of this study is to evaluate the immunogenicity and safety profile of CSL425 (CSL's 2009 H1N1 influenza vaccine) in a healthy pediatric population.
- Trial name
- NCT00958243
- Testing
- CSL's 2009 H1N1 Influenza Vaccine (CSL425)
- Where
- 13 sites in United States
- Volunteers
- 473 people, healthy volunteers welcome
- Sponsor
- Seqirus